Ho Leonard, Zhong Claire C W, Wong Charlene H L, Wu Justin C Y, Chan Karina K H, Wu Irene X Y, Leung Ting Hung, Chung Vincent C H
School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.
The Jockey Club School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.
Chin Med. 2021 Dec 20;16(1):140. doi: 10.1186/s13020-021-00556-6.
BACKGROUND: Prokinetic is the first-line conventional treatment for functional dyspepsia (FD) in Asia despite potential adverse events. Chinese herbal medicine (CHM) may be an effective and safe substitution. This network meta-analysis (NMA) aimed to evaluate the comparative effectiveness of different CHM formulae for FD against prokinetics. METHODS: Seven international and Chinese databases were searched from their inception to July 2020 for randomised controlled trials (RCTs) on CHM versus prokinetics. Data from each RCT were first pooled using random-effect pairwise meta-analyses and illustrated as risk difference (RD) or standardised mean difference (SMD) with 95% confidence interval (CI). Random-effect NMAs were then performed to evaluate the comparative effectiveness of CHM formulae and displayed as RD with 95% CI or SMD with 95% credible interval (CrI). The GRADE partially contextualised framework was applied for NMA result interpretation. RESULTS: Twenty-six unique CHM formulae were identified from twenty-eight RCTs of mediocre quality. Pairwise meta-analyses indicated that CHM was superior to prokinetics in alleviating global symptoms at 4-week follow-up (pooled RD: 0.14; 95% CI: 0.10-0.19), even after trim and fill adjustment for publication bias. NMAs demonstrated that Modified Zhi Zhu Decoction may have a moderate beneficial effect on alleviating global symptoms at 4-week follow-up (RD: 0.28; 95% CI: - 0.03 to 0.75). Xiao Pi Kuan Wei Decoction may have a large beneficial effect on alleviating postprandial fullness (SMD: - 2.14; 95% CI: - 2.76 to 0.70), early satiety (SMD: - 3.90; 95% CI: - 0.68 to - 0.42), and epigastric pain (SMD: - 1.23; 95% CI: - 1.66 to - 0.29). No serious adverse events were reported. CONCLUSION: Modified Zhi Zhu Decoction and Xiao Pi Kuan Wei Decoction may be considered as an alternative for patients unresponsive to prokinetics. Confirmatory head-to-head trials should be conducted to investigate their comparative effectiveness against prokinetics.
背景:尽管可能存在不良事件,但促动力药是亚洲功能性消化不良(FD)的一线常规治疗方法。中药可能是一种有效且安全的替代方法。这项网络荟萃分析(NMA)旨在评估不同中药方剂治疗FD相对于促动力药的比较疗效。 方法:检索了7个国际和中国数据库,从建库至2020年7月,查找关于中药与促动力药对比的随机对照试验(RCT)。首先使用随机效应成对荟萃分析汇总每个RCT的数据,并以风险差(RD)或标准化均数差(SMD)及95%置信区间(CI)表示。然后进行随机效应NMA,以评估中药方剂的比较疗效,并以95%CI的RD或95%可信区间(CrI)的SMD表示。采用GRADE部分情境化框架对NMA结果进行解释。 结果:从28项质量中等的RCT中确定了26种独特的中药方剂。成对荟萃分析表明,在4周随访时,中药在缓解总体症状方面优于促动力药(合并RD:0.14;95%CI:0.10 - 0.19),即使在对发表偏倚进行剪补调整后也是如此。NMA表明,加味枳术汤在4周随访时对缓解总体症状可能有中度有益作用(RD:0.28;95%CI: - 0.03至0.75)。消痞宽胃汤在缓解餐后饱胀(SMD: - 2.14;95%CI: - 2.76至 - 0.70)、早饱(SMD: - 3.90;95%CI: - 0.68至 - 0.42)和上腹部疼痛(SMD: - 1.23;95%CI: - 1.66至 - 0.29)方面可能有较大有益作用。未报告严重不良事件。 结论:加味枳术汤和消痞宽胃汤可被视为对促动力药无反应患者的替代选择。应进行确证性的头对头试验,以研究它们相对于促动力药的比较疗效。
J Ethnopharmacol. 2022-1-30
Therap Adv Gastroenterol. 2018-7-16
BMC Gastroenterol. 2017-6-26
Front Physiol. 2022-6-8
J Ethnopharmacol. 2022-1-30
Neurogastroenterol Motil. 2021-2
Lancet. 2020-11-21
J Neurogastroenterol Motil. 2020-1-30
BMC Med Res Methodol. 2019-10-22